Catherine M. Sevigny

Catherine M. Sevigny

Auto-generated profile, based on publicly available information

Catherine M. Sevigny

Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington D.C.

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2019 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
SSSurojeet Sengupta
Surojeet Sengupta
CSCatherine M. Sevigny
Catherine M. Sevigny
PBPoulomi Bhattacharya
Poulomi Bhattacharya
VJV. Craig Jordan
V. Craig Jordan
RCRobert Clarke
Robert Clarke
Approximately 30% of aromatase-inhibitor–resistant, estrogen receptor–positive patients with breast cancer benefit from treatment with estrogen. This enigmatic estrogen action is not well understood and how it occurs remains elusive. Studies indicate that the unfolded protein response and apoptosis pathways play important roles in mediating estrogen-triggered apoptosis. Using MCF7:5C cells, which mimic aromatase inhibitor resistance, and are hypersensitive to estrogen as evident by induction of apoptosis, we define increased global protein translational load as the trigger for estrogen-induced apoptosis. The protein kinase RNA-like endoplasmic reticulum kinase pathway was activated followed by increased phosphorylation of eukaryotic initiation factor-2 alpha (eIF2α). These actions block global protein translation but preferentially allow high expression of specific transcription factors, such as activating transcription factor 4 and C/EBP homologous protein that facilitate apoptosis. Notably, we recapitulated this phenotype of MCF7:5C in two other endocrine therapy–resistant cell lines (MCF7/LCC9 and T47D:A18/4-OHT) by increasing the levels of phospho-eIF2α using salubrinal to pharmacologically inhibit the enzymes responsible for dephosphorylation of eIF2α, GADD34, and CReP. RNAi-mediated ablation of these genes induced apoptosis that used the same signaling as salubrinal treatment. Moreover, combining 4-hydroxy tamoxifen with salubrinal enhanced apoptotic potency. Implications: These results not only elucidate the mechanism of estrogen-induced apoptosis but also identify a drugable target for potential therapeutic intervention that can mimic the beneficial effect of estrogen in some breast cancers.

1 July 2018 in Cancer Research
Verified
Journal Article
Closed access
SSSurojeet Sengupta
Surojeet Sengupta
CSCatherine M. Sevigny
Catherine M. Sevigny
XLXiaoyi Liu
Xiaoyi Liu
LJLu Jin
Lu Jin
PPPaula R Pohlmann
Paula R Pohlmann
RCRobert Clarke
Robert Clarke
Reprogrammed glucose metabolism is recognized as one of the hallmarks of cancer. High energy demand in cancer cells leads to increased glycolysis to maintain anabolic processes that may be driven by altered enzyme levels. The second committed step in the glycolysis pathway is catalyzed by phosphofructokinase1 (PFK1), which converts fructose-6 phosphate (F6P) to fructose 1,6-bisphosphate (F1,6BP). Another enzyme, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), converts F6P to fructose 2,6-bisphosphate (F2,6BP) that then functions as an allosteric activator of PFK1 and drives glycolysis. PFKFB3 enzyme is upregulated in many cancers including breast cancers. PFKFB3 is regulated by estrogen in ER-positive breast cancer cells but its role in endocrine-therapy resistant breast cancer cells is largely unknown. We investigated the expression of PFKFB3 mRNA and protein in estrogen-responsive MCF7 cells and compared it with LCC9 cells that are estrogen-independent and resistant to 4-hydroxytamoxifen (4OHT) and fulvestrant (Fulv). Twofold higher PFKFB3 mRNA and protein levels were expressed in LCC9 cells compared to MCF7 cells. In addition, the estrogen-mediated stimulation of PFKFB3 that was evident in MCF7 cells was not observed in LCC9 cells. We further studied the effect of pharmacological inhibition of PFKFB3, on the growth of therapy-resistant breast cancer cells using a compound PFK158, a potent inhibitor of the PFKFB3 enzyme. Treatment with PFK158 inhibited the growth of LCC9 cells as well as another cell line, MCF7:5C that is also resistant to 4OHT and partially resistant to Fulv. PFK158 alone was effective in suppressing the growth of both the cell lines at a concentration of 5 µM or higher. Notably, combining PFK158 with either 4OHT or Fulv significantly potentiated the effect of PFK158 treatment in blocking the growth of the cells. In MCF7:5C cells the combination treatment of 2.5 µM PFK158 and Fulv (500nM) or 4OHT(500nM) inhibited cell growth by ~70% as compared to ~30% inhibition in the presence of PFK 158 alone. In LCC9 cells >70% of growth was inhibited in the combination treatment as compared to no inhibition when PFK158, 2.5 µM or 4OHT or Fulv alone was used. In publicly available datasets of ER+, node-negative breast cancer patients, high expression of PFKFB3 was associated with adverse recurrence-free survival (hazard ratio = 4.12 and p= 5.5x10-5). Our study shows an increased basal expression of PFKFB3 mRNA and protein in estrogen-independent, endocrine-therapy resistant breast cancer cells as compared to estrogen-responsive breast cancer cells. Targeting PFKFB3 in combination with anti-estrogens should be explored for potential therapeutic intervention in endocrine therapy-resistant breast cancers. Citation Format: Surojeet Sengupta, Catherine M. Sevigny, Xiaoyi Liu, Lu Jin, Paula R. Pohlmann, Robert Clarke. Targeting glycolysis enzyme, PFKFB3, in endocrine therapy resistant breast cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 907.

3 April 2023
Verified
Other
Open access
SSSurojeet Sengupta
Surojeet Sengupta
CSCatherine M. Sevigny
Catherine M. Sevigny
PBPoulomi Bhattacharya
Poulomi Bhattacharya
VJV. Craig Jordan
V. Craig Jordan
RCRobert Clarke
Robert Clarke
Fulvestrant potentiates the apoptotic effect of salubrinal in MCF7:5C and LCC9 cells.

3 April 2023
Verified
Other
Open access
SSSurojeet Sengupta
Surojeet Sengupta
CSCatherine M. Sevigny
Catherine M. Sevigny
PBPoulomi Bhattacharya
Poulomi Bhattacharya
VJV. Craig Jordan
V. Craig Jordan
RCRobert Clarke
Robert Clarke
Salubrinal treatment increases annexin V positive cells

3 April 2023
Verified
Other
Open access
SSSurojeet Sengupta
Surojeet Sengupta
CSCatherine M. Sevigny
Catherine M. Sevigny
PBPoulomi Bhattacharya
Poulomi Bhattacharya
VJV. Craig Jordan
V. Craig Jordan
RCRobert Clarke
Robert Clarke
Similar Regulation of additional UPR genes by estrogen and salubrinal in MCF7:5C cells.

3 April 2023
Verified
Other
Open access
SSSurojeet Sengupta
Surojeet Sengupta
CSCatherine M. Sevigny
Catherine M. Sevigny
PBPoulomi Bhattacharya
Poulomi Bhattacharya
VJV. Craig Jordan
V. Craig Jordan
RCRobert Clarke
Robert Clarke
Effect of 17β-estradiol (E2), 4-hydroxytamoxifen (4OHT), Fulvestratnt (Ful), and its combination on LCC9, T47D:A18 and T47D:A18/4-OHT cells.